The treatment of the remaining vast majority of mCRC patients (who are microsatellite stable—MSS) is still based upon only a few molecular and/or clinical determinants: sidedness of the primary tumor location, RAS and BRAF mutational status [26]. Here, BRAF is linked to neoplasm.